SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare advances on receiving nod to merge Navya Biologicals with itself

28 Jun 2016 Evaluate

Shilpa Medicare is currently trading at Rs. 498.70, up by 13.90 points or 2.87% from its previous closing of Rs. 484.80 on the BSE.

The scrip opened at Rs. 490.15 and has touched a high and low of Rs. 515.00 and Rs. 490.15 respectively. So far 11,097 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 623.35 on 05-Aug-2015 and a 52 week low of Rs. 355.00 on 20-Jan-2016.

Last one week high and low of the scrip stood at Rs. 515.00 and Rs. 442.00 respectively. The current market cap of the company is Rs. 3,669.00 crore.

The promoters holding in the company stood at 53.05%, while Institutions and Non-Institutions held 14.83% and 32.12% respectively.

Shilpa Medicare has received an approval for amalgamation of Navya Biologicals (NBPL) with itself. The merger is however subject to the approval/observation letters of requisite statutory bodies/ intermediaries including Stock Exchanges, shareholders and High Court of Karnataka/ National Company Law Tribunal and will be completed in 7 to 8 months.

The board of directors at their meeting held on June 27, 2016 has considered and approved for the same based on the recommendations of Audit Committee. The company’s board has approved the acquisition of NBPL in exchange for 14 lakh shares of company to be issued to the shareholders of NBPL.

NBPL is a company incorporated under the Companies Act, engaged in research and development activities in the field of biologicals. NBPL has specifically been in the development of bio-similars and bioprocess technology platforms.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×